Medpace Holdings (01P) Stock Overview
Provides clinical research-based drug and medical device development services in North America, Europe, Asia, South America, Africa, and Australia. More details
| Snowflake Score | |
|---|---|
| Valuation | 5/6 |
| Future Growth | 3/6 |
| Past Performance | 3/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
01P Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Medpace Holdings, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$353.00 |
| 52 Week High | US$558.20 |
| 52 Week Low | US$250.00 |
| Beta | 1.39 |
| 1 Month Change | -9.65% |
| 3 Month Change | -29.27% |
| 1 Year Change | 35.56% |
| 3 Year Change | 94.60% |
| 5 Year Change | 153.96% |
| Change since IPO | 1,263.78% |
Recent News & Updates
Recent updates
Shareholder Returns
| 01P | DE Life Sciences | DE Market | |
|---|---|---|---|
| 7D | -21.3% | -6.5% | -2.0% |
| 1Y | 35.6% | -15.3% | 3.5% |
Return vs Industry: 01P exceeded the German Life Sciences industry which returned -15.7% over the past year.
Return vs Market: 01P exceeded the German Market which returned 3.7% over the past year.
Price Volatility
| 01P volatility | |
|---|---|
| 01P Average Weekly Movement | 9.1% |
| Life Sciences Industry Average Movement | 8.9% |
| Market Average Movement | 5.9% |
| 10% most volatile stocks in DE Market | 13.3% |
| 10% least volatile stocks in DE Market | 2.6% |
Stable Share Price: 01P's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: 01P's weekly volatility (9%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1992 | 6,300 | August Troendle | www.medpace.com |
Medpace Holdings, Inc. provides clinical research-based drug and medical device development services in North America, Europe, Asia, South America, Africa, and Australia. The company offers a suite of services supporting the clinical development process from Phase I to Phase IV in various therapeutic areas. It provides clinical development services to the pharmaceutical, biotechnology, and medical device industries; and development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance new drug application submissions, and post-marketing clinical support services.
Medpace Holdings, Inc. Fundamentals Summary
| 01P fundamental statistics | |
|---|---|
| Market cap | €10.00b |
| Earnings (TTM) | €392.77m |
| Revenue (TTM) | €2.28b |
Is 01P overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 01P income statement (TTM) | |
|---|---|
| Revenue | US$2.68b |
| Cost of Revenue | US$752.59m |
| Gross Profit | US$1.93b |
| Other Expenses | US$1.47b |
| Earnings | US$460.40m |
Last Reported Earnings
Mar 31, 2026
Next Earnings Date
n/a
| Earnings per share (EPS) | 16.12 |
| Gross Margin | 71.90% |
| Net Profit Margin | 17.19% |
| Debt/Equity Ratio | 0% |
How did 01P perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/04/27 03:57 |
| End of Day Share Price | 2026/04/27 00:00 |
| Earnings | 2026/03/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Medpace Holdings, Inc. is covered by 20 analysts. 12 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Eric Coldwell | Baird |
| Luke Sergott | Barclays |
| Sean Dodge | BMO Capital Markets Equity Research |